bl-m07d1
Small moleculeexperimental
Clinical trial activity
15 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
11
Phase 3
6
Phase 4
0
Earliest trial started Aug 9, 2022 (NCT05461768)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Biliary Tract Neoplasms · Phase 1
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Transitional Cell · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 3
- Genital Neoplasms, Female · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Stomach Neoplasms · Phase 3
- Urologic Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2ANTAGONIST
ERBB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07264816 | Phase 2 | Dec 31, 2025 | Baili Pharmaceutical Group |
| NCT07178795 | Phase 3 | Sep 29, 2025 | Baili Pharmaceutical Group |
| NCT07152405 | Phase 3 | Sep 24, 2025 | Baili Pharmaceutical Group |
| NCT06891833 | Phase 2/Phase 3 (Phase 3) | Jun 5, 2025 | Baili Pharmaceutical Group |
| NCT06830889 | Phase 3 | May 31, 2025 | Baili Pharmaceutical Group |
| NCT06957886 | Phase 3 | May 15, 2025 | Baili Pharmaceutical Group |
| NCT06423885 | Phase 2 | Oct 31, 2024 | Baili Pharmaceutical Group, Fudan University |
| NCT06445400 | Phase 2 | Jun 19, 2024 | Baili Pharmaceutical Group, Sun Yat-Sen University |
| NCT06316531 | Phase 3 | May 8, 2024 | Baili Pharmaceutical Group, Sun Yat-Sen University |
| NCT06293898 | Phase 1 | Feb 9, 2024 | SystImmune Inc. |
| NCT06131450 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences |
| NCT06114511 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Baili Pharmaceutical Group, Sun Yat-Sen University |
| NCT06031584 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2023 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences |
| NCT05631964 | Phase 1 | Dec 31, 2022 | Baili Pharmaceutical Group, SystImmune Inc. |
| NCT05461768 | Phase 1 | Aug 9, 2022 | Baili Pharmaceutical Group, SystImmune Inc. |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 14 | 14 | 3 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 0 | 2 | 2023 |
| SystImmune Inc. | For profit | 3 | 1 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1